North American Consortium for Histiocytosis Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Memphis Tennessee United States (2014)

Organization Overview

First Clinical Trial
2014
NCT02205762
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

North American Consortium for Histiocytosis

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Erdheim-Chester Disease (Phase 2)

Histiocytic Disorders, Malignant (Phase 2)

Histiocytic Sarcoma (Phase 2)

Histiocytosis (Phase 3)

Histiocytosis, Langerhans-Cell (Phase 3)

Histiocytosis, Sinus (Phase 2)

Lymphohistiocytosis, Hemophagocytic (Phase 2)

Neurodegenerative Diseases (Phase 2)

Xanthogranuloma, Juvenile (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 14